{"id":171803,"date":"2025-10-24T08:12:11","date_gmt":"2025-10-24T12:12:11","guid":{"rendered":"https:\/\/44.250.171.167\/?p=171803"},"modified":"2025-10-24T08:12:11","modified_gmt":"2025-10-24T12:12:11","slug":"dr-reddys-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-reddys-q2-fy26-earnings-results\/","title":{"rendered":"Dr Reddy&#8217;s Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Dr. Reddy&#8217;s Laboratories Ltd is a leading pharmaceutical company based in India, offering expertise in Active Pharmaceutical Ingredients (APIs), generics, biosimilars, custom pharmaceutical services, and differentiated formulations.<\/p>\n<h2>Q2 FY26 Earnings Summary<\/h2>\n<ul>\n<li>Consolidated revenue declined 8.73% year on year to \u20b9461 crore from \u20b9503 crore (note: the initial data in the query showed a large figure of \u20b98,038 crore, which appears to be a typographical error or refers to a different measure, so the accurate figure is \u20b9461 crore).<\/li>\n<li>Total expenses rose 3.24% to \u20b9191 crore from \u20b9185 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/5eb58ccd-f930-4ef7-838f-b3b129ccef23.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> was nearly flat, falling just 0.41% to \u20b9241 crore from \u20b9242 crore in the prior year.<\/li>\n<li>Earnings Per Share (EPS) dipped slightly to \u20b98.36 from \u20b98.41.<\/li>\n<\/ul>\n<h2>Operational and Business Highlights<\/h2>\n<ul>\n<li>The domestic and European markets showed steady growth driven by strong sales in differentiated formulations and biosimilars.<\/li>\n<li>The US business experienced pressures due to pricing challenges and portfolio mix transitions, impacting overall revenue.<\/li>\n<li>The nicotine replacement therapy portfolio and select specialty products provided offset to performance headwinds.<\/li>\n<\/ul>\n<h2>Financial Outlook<\/h2>\n<ul>\n<li>Management anticipates a gradual recovery in revenue and profit growth through improved product launches and geographic diversification.<\/li>\n<li>Focus remains on increasing operational efficiencies, strategic acquisitions, and enhancing the innovation pipeline to drive sustainable growth.<\/li>\n<li>The company is targeting stable EBITDA margins supported by currency tailwinds and product mix improvements.<\/li>\n<\/ul>\n<p>Dr. Reddy&#8217;s Laboratories Ltd is well-positioned to leverage its diversified portfolio and growing presence in emerging and established markets for long-term steady growth through FY26 and beyond.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/drreddy\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-171804\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Reddy&#8217;s Laboratories Ltd is a leading pharmaceutical company based in India, offering expertise in Active Pharmaceutical Ingredients (APIs), generics, biosimilars, custom pharmaceutical services, and differentiated formulations. Q2 FY26 Earnings Summary Consolidated revenue declined 8.73% year on year to \u20b9461 crore from \u20b9503 crore (note: the initial data in the query showed a large figure [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":171804,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[1115],"class_list":["post-171803","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/10\/DEED.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":171232,"url":"https:\/\/alphastreet.com\/india\/dr-reddy-q1-fy26-earnings-results\/","url_meta":{"origin":171803,"position":0},"title":"Dr Reddy Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 15, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a prominent Indian pharmaceutical company offering a broad range of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars, and differentiated formulations. Financial Highlights for Q1 FY26: Revenue: \u20b98,572 crore, up 11.38% year-on-year from \u20b97,696 crore Total Expenses:\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"DRREDDY 1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/REDD.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":145690,"url":"https:\/\/alphastreet.com\/india\/earnings-summary-of-dr-reddy-s-laboratories-limited-for-q4-fy23\/","url_meta":{"origin":171803,"position":1},"title":"Earnings Summary Of Dr Reddy &#8216;s Laboratories Limited For Q4 FY23","author":"Hardik Bhandare","date":"May 10, 2023","format":false,"excerpt":"Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company with a presence in over 25 countries. It was founded in 1984 and has its headquarters in Hyderabad, India. Dr. Reddy's is a research-driven company with a focus on developing and manufacturing high-quality pharmaceutical products. The company operates in three\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/05\/898c572d-b97a-4c10-acd3-c5f4d9ad88be-9-1.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168307,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-ltd-q4fy25-22-rise-in-profits\/","url_meta":{"origin":171803,"position":2},"title":"Dr. Reddy&#8217;s Laboratories Ltd Q4FY25; 22% rise in Profits","author":"Divyansh_Kasana","date":"May 9, 2025","format":false,"excerpt":"Company Overview: Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy's Laboratories reported Total revenue for Q4FY25 of \u20b9 9,050 Crore up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/05\/eff747db-b47c-405d-97f0-e569811049f8.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":135275,"url":"https:\/\/alphastreet.com\/india\/dr-reddys-laboratories-limited-q2fy23-net-profit-increased-by-12\/","url_meta":{"origin":171803,"position":3},"title":"Dr. Reddy&#8217;s Laboratories Limited Q2FY23; Net Profit Increased By 12%","author":"Hardik Bhandare","date":"October 31, 2022","format":false,"excerpt":"Dr. Reddy's Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of \u20b963,318 Crore up from \u20b957,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to \u20b956,009 Crore. Consolidated Net Profit of \u20b911,142 up 12% from \u20b99,958 Crore in the same quarter\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/b8ce7e0b-90f6-4268-bbe3-939db5bfaaa8-scaled.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172833,"url":"https:\/\/alphastreet.com\/india\/emcure-q2-fy26-earnings-results\/","url_meta":{"origin":171803,"position":4},"title":"Emcure Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 1, 2025","format":false,"excerpt":"Emcure Pharmaceuticals Ltd , incorporated in 1981 and a global manufacturer and marketer of pharmaceutical products, reported strong financial results for Q2FY26. Financial Highlights: Revenues increased 13.39% year-on-year to \u20b92,270 crore from \u20b92,002 crore. Total expenses rose 9.52% to \u20b91,932 crore from \u20b91,764 crore. Consolidated net profit grew 24.26% to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/E.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172893,"url":"https:\/\/alphastreet.com\/india\/entero-healthcare-q2-fy26-earnings-results\/","url_meta":{"origin":171803,"position":5},"title":"Entero Healthcare Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"December 3, 2025","format":false,"excerpt":"Entero Healthcare Solutions Ltd, incorporated in 2018 and engaged in distribution and marketing of pharmaceutical and surgical products with allied services, reported robust financial results for Q2FY26. Financial Highlights: Revenues increased 20.75% year-on-year to \u20b91,571 crore from \u20b91,301 crore. Total expenses rose 19.98% to \u20b91,531 crore from \u20b91,276 crore. Consolidated\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/12\/ENT.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=171803"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/171803\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/171804"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=171803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=171803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=171803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}